AFP-L3 as a Prognostic Predictor of Recurrence in Hepatoblastoma: A Pilot Study.
Adult
Biomarkers, Tumor
/ metabolism
Carcinoma, Hepatocellular
/ pathology
Female
Follow-Up Studies
Humans
Japan
/ epidemiology
Liver Neoplasms
/ pathology
Male
Middle Aged
Neoplasm Recurrence, Local
/ diagnosis
Pilot Projects
Plant Lectins
/ metabolism
Prognosis
Retrospective Studies
Young Adult
alpha-Fetoproteins
/ metabolism
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
24
10
2020
medline:
7
4
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
The α-fetoprotein (AFP) level is a sensitive biomarker of active hepatoblastoma (HB). This study aimed to clarify whether the Lens culinaris agglutinin A-reactive fraction of AFP (AFP-L3) after complete resection is a prognostic predictor of HB recurrence. Fourteen HB patients who underwent complete resection of HB were divided into the recurrence group (RG, n=4) and the non-recurrence group (NRG, n=10). The AFP level and AFP-L3 before and after radical surgery were compared between the 2 groups. There was no significant difference in AFP levels in the early postoperative period between the 2 groups (P=0.54), and AFP was not an early prognostic factor for HB recurrence. At 2 months after surgery, the AFP-L3 fell below the detection limit only in the NRG (7/10 cases) (NRG=70.0% vs. RG=0%, P=0.03). In addition, there were some cases of recurrence in those whose AFP level decreased to the normal range, but none in those whose AFP-L3 fell below the detection limit. In conclusion, the AFP-L3 decreased earlier than did the AFP level; thus, the AFP-L3 after complete resection may be a predictor for HB recurrence.
Identifiants
pubmed: 33093349
doi: 10.1097/MPH.0000000000001971
pii: 00043426-202101000-00027
doi:
Substances chimiques
AFP protein, human
0
Biomarkers, Tumor
0
Plant Lectins
0
alpha-Fetoproteins
0
lentil lectin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e76-e79Références
Meyers RL. Tumors of the liver in children. Surg Oncol. 2007;16:195–203.
Ng K, Mogul DB. Pediatric liver tumors. Clin Liver Dis. 2018;22:753–772.
Lovvorn HN III, Ayers D, Zhao Z, et al. Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics. J Pediatr Surg. 2010;45:121–128.
Kinoshita Y, Tajiri T, Souzaki R, et al. Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors. J Pediatr Hematol Oncol. 2008;30:447–450.
Tsuchida Y, Kaneko M, Fukui M, et al. Three different types of alpha-fetoprotein in the diagnosis of malignant solid tumors: use of a sensitive lectin-affinity immunoelectrophoresis. J Pediatr Surg. 1989;24:350–355.
Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313:15–19.
Aoyagi Y, Suzuki Y, Isemura M, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer. 1988;61:769–774.
Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive α-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993;53:5419–5423.
Kobayashi M, Hosaka T, Ikeda K, et al. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res. 2011;41:1036–1045.
Lai Q, Melandro F, Pinheiro RS, et al. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103.
Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine. 2017;96:e5811.
Kumada T, Nakano S, Takeda I, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol. 1999;30:125–130.
Yamashiki N, Seki T, Wakabayashi M, et al. Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. Oncol Rep. 1999;6:1229–1232.
Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339–364.
Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg. 2002;37:851–856.
Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int. 2011;27:1–8.
Fukuzawa H, Urushihara N, Fukumoto K, et al. Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein response during preoperative chemotherapy? Pediatr Surg Int. 2012;28:887–891.
Koh KN, Park M, Kim BE, et al. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatr Blood Cancer. 2011;57:554–560.
Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:1190–1197.
Kondo R, Kato S, Kaneko K. Congenital hepatoblastoma treated by combination of chemotherapy and resection of the right lobe and caudate lobe. J Jpn Pediatr Soc. 2016;52:982–986.